CD19 and acute lymphoblastic leukemia: In the past few years, CAR T cells targeting Cluster of Differentiation 19 (CD19) have achieved impressive outcomes in the treatment of patients with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL) [7,8,9].